Oxiracetam is a nootropic drug of the racetam family and a very mild stimulant. Several studies suggest that the substance is safe even when high doses are consumed for a long period of time. However, the mechanism of action of the racetam drug family is not fully elucidated; proposed molecular actions include positive allosteric modulation of ionotropic glutamate receptors including AMPA subtype, modulatory effects on NMDA receptor-mediated signaling, enhancement of cholinergic neurotransmission via increased presynaptic acetylcholine release and changes in choline uptake, and influence on neuronal membrane fluidity and cellular energy metabolism leading to improved synaptic plasticity. Chemically, oxiracetam is 2-(4-hydroxy-2-oxopyrrolidin-1-yl)acetamide (CAS 62613-82-5), molecular formula C6H10N2O3, and molecular weight 158.16 g mol-1. It appears as a white crystalline powder, is freely soluble in water and polar solvents, has a melting range near 164 to 166 degrees Celsius, and is commonly characterized and quantified by reverse phase HPLC and LC-MS for research and quality control. Typical research dosing ranges reported in the literature are in the several hundred to low thousands of milligrams per day, and pharmacokinetic studies indicate rapid oral absorption with renal elimination as the primary excretion route.
Parent: Oxiracetam
Parent: Oxiracetam
Parent: Oxiracetam
Pharmaceutical grade oxiracetam is routinely manufactured and released with high purity by HPLC, commonly greater than 98.5 to 99.5 percent area by HPLC assay. Typical specification frameworks follow ICH impurity principles with total related substances often limited to below 0.5 to 1.0 percent by area, and individual unspecified impurities typically limited to less than 0.1 to 0.2 percent. Common related compounds detected during synthesis and storage include deacetylated derivatives, minor oxidative products of the pyrrolidone ring, ring-opened hydrolysis species and low level positional isomers; individual levels for these species are generally observed in the range 0.01 to 0.3 percent depending on process control. Residual solvents are controlled per ICH Q3C and are normally below specified ppm limits, water content by Karl Fischer is typically below 0.5 percent, and heavy metal content is monitored and kept within pharmacopeial limits. Identification and quantification of these impurities are routinely performed using a combination of HPLC with UV detection, LC-MS for structural confirmation, and GC for volatile profile.
Oxiracetam is used in research contexts as a cognitive enhancer candidate and as a tool compound to study mechanisms of synaptic plasticity and cholinergic modulation. In clinical and investigational literature it has been evaluated for effects on learning and memory performance in experimental settings. It is not approved for all indications globally so usage should follow applicable regulatory and clinical guidance.
Oxiracetam modulates central nervous system activity primarily through effects attributed to the racetam family: modulation of glutamatergic receptor function especially AMPA receptors, effects on NMDA-dependent signaling, enhancement of cholinergic neurotransmission, and modulation of neuronal membrane and metabolic properties that support synaptic plasticity. The exact molecular targets and their clinical relevance remain under investigation.
Typical quality specifications for research or pharmaceutical grade oxiracetam report assay values above 98.5 percent by HPLC, total related substances below 0.5 to 1.0 percent, and individual unspecified impurities generally limited to below 0.1 to 0.2 percent. Residual solvents, water content and heavy metals are controlled to ICH and pharmacopeial guidelines.
